Thera-SAbDab

SAPELIZUMAB

>   Structural Summary
TherapeuticSapelizumab
TargetIL6R
Heavy ChainQVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Preregistration
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2017
Companies InvolvedChugai Pharmaceutical, Roche
Conditions Approvedna
Conditions ActiveNeuromyelitis optica
Conditions DiscontinuedRheumatoid arthritis
NotesSatralizumab and Sapelizumab are the same mAb

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]